To reach the next value inflection
LicenseRx asset brief
Phorboxazole compounds as potent anti-tumor agents
Probability of Success
14% · grade C · Medium data confidence
Model PoS 14% (grade C, medium data confidence). Strongest signals: Indication pull, Data maturity. Biggest drag: IP position.
Data maturity (22%)
46
Early / Discovery; in vivo data, human data.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
66
Biologic/antibody -- solid path but higher CMC burden.
Indication pull (14%)
79
Oncology, Neurology -- active buyer appetite.
Competitive whitespace (12%)
66
Crowded oncology field; multi-modal differentiation.
Translational evidence (12%)
62
Public evidence mentions: human, in vivo.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →